Whistleblower Law Blog
Novartis and U.S. Attorney’s Office Settle FCA and Criminal Allegations Regarding Trileptal® for $422.5 Million
Novartis Pharmaceuticals reached a settlement agreement totaling $422.5 million with the U.S. Attorney’s Office for the Eastern District of Pennsylvania regarding civil allegations under the False Claims Act and criminal allegations under the Food, Drug, and Cosmetic Act relating to its misbranding of Trileptal®.
Tagged: False Claims Act (FCA), Whistleblower Laws (Federal)
The Employment Law Group® law firm produces this blog to provide general news and information about the field of whistleblower law. The blog does not contain any legal advice upon which you should rely or act. Please read our disclaimer.
Editor-in-Chief
R. Scott Oswald
Contributing Editor
Laurence Hooper
Popular Topics
- Administrative Review Board (ARB)
- Dodd-Frank Act
- False Claims Act (FCA)
- Foreign Corrupt Practices Act (FCPA)
- Internal Revenue Service (IRS)
- Medicare Fraud
- Occupational Safety and Health Administration (OSHA)
- Sarbanes-Oxley Act (SOX)
- Securities and Exchange Commission (SEC)
- Securities Fraud
- Tax Fraud
- Title VII of the Civil Rights Act of 1964
- Whistleblower Protection Act (WPA)
